Dr Peter R. Paradiso recently retired as Vice President of New Business and Scientific Affairs for Pfizer Vaccines, a Division of Pfizer Inc, in Collegeville, Pennsylvania. In this position, Dr Paradiso was responsible for global scientific affairs and strategic planning within the vaccine research and development group and for commercial oversight of products in development. He is currently working as a consultant in the vaccine field.
Dr Paradiso has worked in vaccine development for over 30 years. He has published extensively in the field of paediatric vaccines, especially in the areas of glycoconjugates, combination vaccines and respiratory viral vaccines. Dr Paradiso worked in the development of pneumococcal conjugate vaccines for more than 20 years, including Prevenar 13. He has worked towards achieving licensure and incorporation of Prevenar 13 into childhood National Immunization Programs on a global level. Most recently, he worked on the development, licensure and introduction of Prevenar 13 for adults. He has also been involved in the development and global registration of vaccines for Haemophilus influenzae type b, acellular pertussis, rotavirus, Neisseria meningitidis group C, and influenza.
Dr Paradiso has served as a member HHS’s National Vaccine Advisory Committee, the Advisory Council on Immunization for New York State and as liaison member of the CDC’s Advisory Committee on Immunization Practices. Dr Paradiso served as an advisor to the WHO’s Strategic Advisory Group of Experts on vaccines and the Global Alliance for Vaccines and Immunization’s (GAVI) Task Force on Research and Development.